Vercise Genus DBS Systems; Vercise Gevia DBS Systems
Boston Scientific Corp · Decision date Sep 22, 2026
What did the FDA approve?
The FDA database entry records an approval decision dated 2026-09-22 for supplement P150031/S098 to Boston Scientific's PMA P150031, covering the Vercise Genus and Vercise Gevia DBS Systems. The supplement falls under the Real-Time Process pathway with the stated reason "Change Design/Components/Specifications/Material." The decision statement describes approval for an alternate battery for charger devices SC-5312 and NM-5312, used with the company's spinal cord stimulation systems and deep brain stimulation systems, respectively.
The identifier P150031/S098 establishes this as a supplement to the original PMA P150031, not a new approval of the whole system. The listed device category is an implanted electrical stimulator for parkinsonian symptoms, product code NHL, under Neurology. The statement states the purpose of the change but does not supply battery specifications, charger performance data, or independent evidence of safety or clinical effectiveness; the database fields do not disclose which battery component or material changed beyond the stated alternate battery.
FDA approval order statement
approval for an alternate battery for the Charger devices SC-5312 and NM-5312 which are used with the Boston Scientific Spinal Cord Stimulation (SCS) systems and Deep Brain Stimulation (DBS) systems, respectively.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 22, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150031/S098
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- Decision code
- APPR
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150031 · Original PMA
VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
P150031/S098 received
Application receipt date recorded by FDA.
P150031/S084 · Related supplement
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM
P150031/S098 · FDA decision
Real-Time Process
P150031/S100 · Related supplement
Vercise DBS Systems
P150031/S102 · Related supplement
Vercise Deep Brain Stimulation (DBS) Systems
Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Dec 8, 2017 | FDA | |
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEMP150031/S084 | Boston Scientific Corp | PMA supplement | Sep 13, 2026 | FDA |
Vercise DBS SystemsP150031/S100 | Boston Scientific Corp | PMA supplement | Oct 15, 2026 | FDA |
Vercise Deep Brain Stimulation (DBS) SystemsP150031/S102 | Boston Scientific Corp | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P150031/S098
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
